We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cervical Cancer Screening Overused in Some Groups

By LabMedica International staff writers
Posted on 11 Dec 2013
National organizations recommended against Papanicolaou testing, a method of cervical screening that is used to detect potentially precancerous and cancerous processes in the endocervical canal, for women without a cervix following a hysterectomy.

The organizations also suggest the test be not performed on those who do not have a history of high-grade precancerous lesion or cervical cancer and for women older than 65 years because the risk of developing this slow-growing cancer is very small at such a late stage in life, as well as on those who had adequate prior screening and who are not at high risk.

Scientists at the University of Utah (Salt Lake City, UT, USA) examined data from the 2010 US National Health Interview Survey, an annual health survey of representative samples of the entire USA population since 1957. More...
The 2010 survey included the most recent cancer control supplement, which is included every three to five years. They investigated the timing of most recent Papanicolaou test, within the past year, one to three years ago, or more than three years ago by sociodemographic characteristics and by hysterectomy status.

Among women reporting a hysterectomy, 34.1% reported a Papanicolaou test in the past year. A total of 64.8% of women reporting a hysterectomy also reported a recent Papanicolaou test since their hysterectomy, and among women 65 years and older without a hysterectomy, 58.4% reported receipt of a Papanicolaou test in the past three years, together representing approximately 14 million women.

Deanna Kepka, PhD, MPH, the lead author from the Huntsman Cancer Institute (Salt Lake City, UT, USA) said, “We knew there would be overuse of Pap tests, because the few studies of cervical cancer screening showed overuse ten years ago, but we were shocked to see so little change over the past ten years. We're hoping to see better use of the tests over the next decade as changes in the health care infrastructure take place. Electronic medical records, health care provider reminder systems, decision support, and new strategies to improve the quality of care may promote guideline-consistent practices among clinicians.” The study was published on November 25, 2013, in the Journal of the American Medical Association Internal Medicine.

Related Links:

University of Utah
Huntsman Cancer Institute 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Automatic CLIA Analyzer
Shine i6000
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.